Atopic Dermatitis (Eczema) clinical trials at UCSF
4 research studies open to eligible people

  • A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18-75

    This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

    Fresno, California and other locations

  • Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis

    open to eligible people ages 18 years and up

    This is a single-arm, open-label study to examine the effect of dupilumab on the immunologic and genetic environment within atopic dermatitis skin lesions.

    San Francisco, California

  • Systemic Therapies for Pediatric Atopic Dermatitis

    open to eligible people ages 2-17

    While many patients with atopic dermatitis (eczema) can be managed with topical creams and treatments for itch, some children have such severe, long-standing disease that they need treatment with oral medications that decrease the ability of the immune system to react. However, there is not enough information on the proper use of these medications or how well they work compared with each other. The current study looks at the response of children treated with these medications to provide this information and improve their use.

    San Francisco, California and other locations

  • The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

    open to eligible people ages 18 years and up

    This is a single-arm, open-label study, which will examine the effect of dupilumab on quality of life in atopic dermatitis patients.

    San Francisco, California

Last updated: